BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McElroy DL, Roebuck AJ, Scott GA, Greba Q, Garai S, Denovan-Wright EM, Thakur GA, Laprairie RB, Howland JG. Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies. Psychopharmacology (Berl) 2021;238:1087-98. [PMID: 33442771 DOI: 10.1007/s00213-020-05755-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Garai S, Schaffer PC, Laprairie RB, Janero DR, Pertwee RG, Straiker A, Thakur GA. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Bioorg Med Chem 2021;50:116421. [PMID: 34634617 DOI: 10.1016/j.bmc.2021.116421] [Reference Citation Analysis]
2 Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. Int J Mol Sci 2021;22:9472. [PMID: 34502379 DOI: 10.3390/ijms22179472] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
3 Roebuck AJ, Greba Q, Smolyakova AM, Alaverdashvili M, Marks WN, Garai S, Baglot SL, Petrie G, Cain SM, Snutch TP, Thakur GA, Hill MN, Howland JG, Laprairie RB. Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. Neuropharmacology 2021;190:108553. [PMID: 33845076 DOI: 10.1016/j.neuropharm.2021.108553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]